RJA
VRTX icon

Ross\Johnson & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Ross\Johnson & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$447 Sell
1
-1
-50% -$466 0.01% 110
2025
Q4 		$907 Buy
2
+1
+100% +$431 0.02% 104
2025
Q3 		$392 Hold
1
– – 0.01% 121
2025
Q2 		$445 Sell
1
-4
-80% -$1.84K 0.01% 107
2025
Q1 		$2.42K Buy
+5
New +$2.33K 0.04% 149

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ross\Johnson & Associates's VRTX Position: Q1 2026 in Review

Ross\Johnson & Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 50% in Q1 2026, selling an estimated $466 and leaving 1 share worth $447. The position accounts for 0.01% of the portfolio, ranked #110.

Ross\Johnson & Associates first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.42K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Ross\Johnson & Associates held 1 share of Vertex Pharmaceuticals worth $447 as of Q1 2026.
  • Ross\Johnson & Associates sold 1 Vertex Pharmaceuticals share in Q1 2026, an estimated $466.
  • Vertex Pharmaceuticals made up 0.01% of Ross\Johnson & Associates's portfolio in Q1 2026, its #110 holding.
  • Ross\Johnson & Associates first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Ross\Johnson & Associates's Vertex Pharmaceuticals position peaked at $2.42K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.